CN1520837A - 一种治疗内毒素血症的植物提取物、化合物及其提取方法和用途 - Google Patents
一种治疗内毒素血症的植物提取物、化合物及其提取方法和用途 Download PDFInfo
- Publication number
- CN1520837A CN1520837A CNA031020658A CN03102065A CN1520837A CN 1520837 A CN1520837 A CN 1520837A CN A031020658 A CNA031020658 A CN A031020658A CN 03102065 A CN03102065 A CN 03102065A CN 1520837 A CN1520837 A CN 1520837A
- Authority
- CN
- China
- Prior art keywords
- acid
- chemical compound
- effective site
- indole
- endotoxemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- 238000000605 extraction Methods 0.000 title claims description 19
- 239000002158 endotoxin Substances 0.000 title description 14
- 239000000419 plant extract Substances 0.000 title description 3
- 208000019838 Blood disease Diseases 0.000 title 1
- 208000014951 hematologic disease Diseases 0.000 title 1
- 208000018706 hematopoietic system disease Diseases 0.000 title 1
- 208000037487 Endotoxemia Diseases 0.000 claims abstract description 40
- 230000000694 effects Effects 0.000 claims abstract description 15
- -1 furfuraldehyde compound Chemical class 0.000 claims abstract description 15
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims abstract description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 10
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims abstract description 9
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920005610 lignin Polymers 0.000 claims abstract description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
- 150000004668 long chain fatty acids Chemical class 0.000 claims abstract description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 5
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 3
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 3
- 229960004365 benzoic acid Drugs 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 25
- 239000011347 resin Substances 0.000 claims description 23
- 229920005989 resin Polymers 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 21
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 claims description 20
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- 239000010231 banlangen Substances 0.000 claims description 16
- 241000218652 Larix Species 0.000 claims description 15
- 235000005590 Larix decidua Nutrition 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 239000003208 petroleum Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 208000006454 hepatitis Diseases 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 5
- 206010040070 Septic Shock Diseases 0.000 claims description 5
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 5
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003729 cation exchange resin Substances 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 3
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 3
- 230000001986 anti-endotoxic effect Effects 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241000792859 Enema Species 0.000 claims description 2
- 208000002720 Malnutrition Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 102000011759 adducin Human genes 0.000 claims description 2
- 108010076723 adducin Proteins 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 229940095399 enema Drugs 0.000 claims description 2
- 239000002024 ethyl acetate extract Substances 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 208000003243 intestinal obstruction Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 230000001071 malnutrition Effects 0.000 claims description 2
- 235000000824 malnutrition Nutrition 0.000 claims description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 206010042772 syncope Diseases 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 229960001866 silicon dioxide Drugs 0.000 claims 1
- OGFXBIXJCWAUCH-KPHUOKFYSA-N (+)-isolariciresinol Chemical compound C1([C@@H]2[C@@H](CO)[C@H](CO)CC=3C=C(C(=CC=32)O)OC)=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-KPHUOKFYSA-N 0.000 abstract description 2
- OEZZQOVAJDAVSJ-UHFFFAOYSA-N isolariciresinol Natural products COc1cc(ccc1O)C1C(CO)C(CO)Cc2cc(O)c(OC)cc12 OEZZQOVAJDAVSJ-UHFFFAOYSA-N 0.000 abstract description 2
- 241000334160 Isatis Species 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical group C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
不同工艺提取组分 | 存活时间(h) | 存活率(%) | X2检验(X2≥3.84) | T检验(P≤0.05) | ||
对照组 | 给药组 | 对照组 | 给药组 | |||
80%乙醇提取部位 | 31.15 | 67.45 | 8/32 | 28/32 | 22.92 | 4.04*10-9 |
阳离子交换树脂流出液醇提取部位 | 38.90 | 59.33 | 12/30 | 23/30 | 6.86 | 3.33*10-3 |
大孔吸附树脂10%-50%醇洗脱部位 | 31.15 | 47.20 | 8/32 | 18/32 | 5.23 | 9.60*10-3 |
氯仿萃取部位 | 24.57 | 45.58 | 4/34 | 17/34 | 9.92 | 3.80*10-4 |
乙酸乙酯萃取部位 | 33.86 | 61.56 | 9/30 | 23/30 | 11.32 | 4.04*10-5 |
正丁醇萃取部位 | 25.62 | 55.40 | 5/30 | 20/30 | 13.44 | 3.17*10-5 |
给药部位编号 | 各部位所占比例(重量比) | 动物试验数据 | ||||
5-HMF | 异落叶松树醇酯 | 1-N-甲氧基-2-氧-吲哚-3-乙酰胺 | 药液pH值 | X2检验(X2≥3.84) | T检验(P≤0.05) | |
给药部位1 | 17.00 | 1.00 | 15.0 | 4.00 | 20.43 | 5.16*10-9 |
给药部位2 | 17.00 | 1.00 | 0.00 | 2.80 | 13.08 | 7.04*10-5 |
给药部位3 | 51.00 | 0.00 | 0.00 | 2.50 | 4.19 | 0.05 |
给药部位4 | 0.00 | 1.00 | 7.5 | 3.80 | 4.22 | 0.01 |
给药部位5 | 0.00 | 1.50 | 0.00 | 3.50 | 3.95 | 0.00 |
给药部位6 | 0.00 | 0.00 | 30.0 | 4.50 | 4.19 | 0.05 |
背景溶液7 | 0.00 | 0.00 | 0.00 | 3.50 | 0.00 | 0.00 |
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03102065 CN1251698C (zh) | 2003-01-30 | 2003-01-30 | 一种治疗内毒素血症的板蓝根提取物和用途 |
CNB2005100753581A CN1324009C (zh) | 2003-01-30 | 2003-01-30 | 化合物1-n-甲氧基-2-氧-吲哚-3-乙酰胺及其药物用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03102065 CN1251698C (zh) | 2003-01-30 | 2003-01-30 | 一种治疗内毒素血症的板蓝根提取物和用途 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510075356 Division CN1286455C (zh) | 2003-01-30 | 2003-01-30 | 5-羟甲基糠醛的药物用途 |
CNB2005100753581A Division CN1324009C (zh) | 2003-01-30 | 2003-01-30 | 化合物1-n-甲氧基-2-氧-吲哚-3-乙酰胺及其药物用途 |
CN 200510075357 Division CN1286469C (zh) | 2003-01-30 | 2003-01-30 | 异落叶松树脂醇的药物用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1520837A true CN1520837A (zh) | 2004-08-18 |
CN1251698C CN1251698C (zh) | 2006-04-19 |
Family
ID=34281581
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03102065 Expired - Fee Related CN1251698C (zh) | 2003-01-30 | 2003-01-30 | 一种治疗内毒素血症的板蓝根提取物和用途 |
CNB2005100753581A Expired - Fee Related CN1324009C (zh) | 2003-01-30 | 2003-01-30 | 化合物1-n-甲氧基-2-氧-吲哚-3-乙酰胺及其药物用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100753581A Expired - Fee Related CN1324009C (zh) | 2003-01-30 | 2003-01-30 | 化合物1-n-甲氧基-2-氧-吲哚-3-乙酰胺及其药物用途 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN1251698C (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101234134B (zh) * | 2008-02-27 | 2011-01-05 | 广州白云山和记黄埔中药有限公司 | 复方板蓝根制剂在制备防治内毒素血症药物中的应用 |
CN101933966A (zh) * | 2010-08-31 | 2011-01-05 | 南京中医药大学 | 板蓝根活性部位组合物及其制备方法及应用 |
CN101385750B (zh) * | 2007-09-14 | 2011-09-28 | 四川省泰信动物药业有限公司 | 板蓝根有效成分的制备方法 |
CN102614206A (zh) * | 2011-01-31 | 2012-08-01 | 澳门科技大学 | 7S,8R,8′R-(+)-落叶松树脂醇-4,4′-二-O-β-D-吡喃葡萄糖苷在制药中的应用 |
CN106565468A (zh) * | 2016-11-15 | 2017-04-19 | 河南中医药大学 | 一种从桑白皮中提取的丁香酸及其制备方法与应用 |
CN109438221A (zh) * | 2018-11-21 | 2019-03-08 | 集美大学 | 一种从螺旋藻中制备丁香酸的方法 |
CN111450135A (zh) * | 2020-05-18 | 2020-07-28 | 山西省芮城县红宝兽药有限责任公司 | 一种高纯度板蓝根及其注射液的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW281669B (zh) * | 1993-02-17 | 1996-07-21 | Chugai Pharmaceutical Co Ltd | |
WO1998002419A1 (fr) * | 1996-07-12 | 1998-01-22 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs de proliferation de cellules cancereuses |
-
2003
- 2003-01-30 CN CN 03102065 patent/CN1251698C/zh not_active Expired - Fee Related
- 2003-01-30 CN CNB2005100753581A patent/CN1324009C/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101385750B (zh) * | 2007-09-14 | 2011-09-28 | 四川省泰信动物药业有限公司 | 板蓝根有效成分的制备方法 |
CN101234134B (zh) * | 2008-02-27 | 2011-01-05 | 广州白云山和记黄埔中药有限公司 | 复方板蓝根制剂在制备防治内毒素血症药物中的应用 |
CN101933966A (zh) * | 2010-08-31 | 2011-01-05 | 南京中医药大学 | 板蓝根活性部位组合物及其制备方法及应用 |
CN102614206A (zh) * | 2011-01-31 | 2012-08-01 | 澳门科技大学 | 7S,8R,8′R-(+)-落叶松树脂醇-4,4′-二-O-β-D-吡喃葡萄糖苷在制药中的应用 |
CN106565468A (zh) * | 2016-11-15 | 2017-04-19 | 河南中医药大学 | 一种从桑白皮中提取的丁香酸及其制备方法与应用 |
CN109438221A (zh) * | 2018-11-21 | 2019-03-08 | 集美大学 | 一种从螺旋藻中制备丁香酸的方法 |
CN109438221B (zh) * | 2018-11-21 | 2021-09-03 | 集美大学 | 一种从螺旋藻中制备丁香酸的方法 |
CN111450135A (zh) * | 2020-05-18 | 2020-07-28 | 山西省芮城县红宝兽药有限责任公司 | 一种高纯度板蓝根及其注射液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1324009C (zh) | 2007-07-04 |
CN1704401A (zh) | 2005-12-07 |
CN1251698C (zh) | 2006-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101711805B (zh) | 一种治疗类风湿性关节炎的药物组合物及其制剂 | |
CN1251698C (zh) | 一种治疗内毒素血症的板蓝根提取物和用途 | |
CN1286455C (zh) | 5-羟甲基糠醛的药物用途 | |
CN101074223A (zh) | 芹菜素衍生物及其治疗糖尿病及并发症的用途 | |
CN1286469C (zh) | 异落叶松树脂醇的药物用途 | |
CN1965853A (zh) | 龙胆苦苷在抗病毒药物中的应用 | |
CN1709417A (zh) | 一种杏香兔耳风提取物及其制备方法 | |
CN1883566A (zh) | 一种消炎药物及其制备方法 | |
CN1098295A (zh) | 知石清解注射液 | |
CN113861135B (zh) | 白木香四醇及其药物组合物与其制备方法和应用 | |
CN1698606A (zh) | 喹诺里西啶类生物碱在制备抗乙肝病毒药物中的用途 | |
CN1141101C (zh) | 治疗乙肝的药物及其制备方法 | |
CN101062046A (zh) | 一种皂苷类成分的医学用途 | |
CN1560061A (zh) | 怀山药提取物怀山药皂甙的提取方法 | |
CN100343266C (zh) | 一种胡黄连总苷提取物及其在制备肝病药物中的应用和制备方法 | |
CN1081922C (zh) | 含人参皂甙Re组分的药物组合物,其制备方法及应用 | |
CN100577176C (zh) | 短瓣金莲花提取物、其抗炎有效成分和它们的用途 | |
WO2022262241A1 (zh) | 连翘叶提取物及其用于提高肠道akk菌丰度的用途 | |
CN1193766C (zh) | 治疗肝炎的栀子总甙组合物及其制备方法 | |
CN1438237A (zh) | 刺囊酸的制备方法、药物制剂及医药新用途 | |
CN1939327A (zh) | 柳川鱼苷、蒙花苷及其组合物的制药用途 | |
CN1872101A (zh) | 具抗病毒作用的小紫金牛提取物及其提取方法和应用 | |
CN1839867A (zh) | 具有清热、泻火和解毒作用的药物组合物 | |
CN1188118C (zh) | 一种预防或治疗癌症的药物及其用途 | |
CN1724527A (zh) | 梣酮作为肝病治疗药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG TIANYI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: PU WENYING Effective date: 20100928 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100011 TO: 163316 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100928 Address after: 163316 Jianshe Road high tech Zone, Heilongjiang, No. 245, Patentee after: Heilongjiang Tianyi Pharmaceutical Co., Ltd. Address before: 100011 Beijing Dongcheng District Andingmen Street No. 21 Building No. 10 15-8 Patentee before: Pu Wenying |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060419 Termination date: 20180130 |
|
CF01 | Termination of patent right due to non-payment of annual fee |